Search

2024 MAY 18 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Kidney Diseases and Conditions - Chronic Kidney [...]

In patients with moderate to severe chronic kidney disease (CKD) and treatment-resistant hypertension, finerenone is associated with less systolic blood pressure reduction, greater proteinuria reduction, and lower rates of hyperkalemia [...]

Longer maintenance therapy with the potassium binder sodium zirconium cyclosilicate (SZC) may reduce hyperkalemia-related hospitalization rates, new research suggests. In the RECOGNIZE I retrospective study, 748 patients (64.9%) received short-term [...]

By the definition of Tintinalli's Emergency Medicine, hyperkalemia is a measured serum potassium of more than 5.5 mEq/L. (1) There is a bit of discrepancy to this value; some texts [...]

Patiromer monotherapy may be effective for acute, non-life-threatening hyperkalemia, investigators reported at Kidney Week 2022, the annual meeting of the American Society of Nephrology. Use of patiromer for chronic hyperkalemia [...]

Mineralocorticoid receptor antagonist (MRA) treatment is associated with increased risk of hyperkalemia in patients with chronic kidney disease (CKD), but the drugs do not increase their risk for death, according [...]

2022 JUN 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on hyperkalemia are discussed in a new report. According to [...]

2021 FEB 13 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Kidney Diseases and Conditions - Diabetic Nephropathy have been [...]

2020 NOV 14 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in Nutritional and Metabolic Diseases and Conditions - [...]

2020 MAY 30 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Nutritional and Metabolic Diseases and Conditions - Hyperkalemia [...]

2018 AUG 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Nutritional and Metabolic Diseases and Conditions - Hyperkalemia have [...]

I recently was contacted by my nurse to schedule follow-up for a patient of mine whose routine labs sent by his cardiologist showed a blood glucose of 48 and a [...]

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.amjmed.2008.10.028 Byline: Apurv Khanna, William B. White Keywords: Antihypertensive drug therapy; Cardiovascular disease; Chronic kidney disease; Hyperkalemia Abstract: The development of hyperkalemia is common in patients with cardiac and kidney disease who are administered drugs that antagonize the renin-angiotensin-aldosterone system (RAAS). As the results of large-scale clinical trials in hypertension, chronic kidney disease, and congestive heart failure demonstrate benefits of RAAS blockade alone or, in some cases, in combination therapies, the incidence of hyperkalemia has increased in clinical practice. Although there is potential for adverse events in the presence of hyperkalemia, there also are potential benefits of RAAS blockers that support their use in high-risk patient populations. Management of hyperkalemia may be improved by identifying the levels of potassium that may potentially induce harm and using appropriate strategies to avert the levels that may be dangerous or life threatening. Author Affiliation: Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Conn Article Note: (footnote) Funding: This work was supported in part by funding from US Department of Defense DAMDW81XWH-05-10060, NIH R01 AG022092, and an unrestricted educational grant from Boehringer-Ingelheim Pharmaceuticals., Conflict of Interest: Dr White discloses that he has received research funding during the previous 12 months from the National Institutes of Health, the Catherine and Patrick Donaghue Foundation, Astra-Zeneca Pharmaceuticals, Inc, Boehringer-Ingelheim Pharmaceuticals, Inc, Novartis, Inc, and Pfizer, Inc. Dr White serves as a safety consultant to Gilead, Inc, Nicox, Inc, Palatin Technologies, Takeda Research Development Group, and Teva Neurosciences, Inc. Dr Khanna discloses he has received an unrestricted educational grant from Boehringer-Ingelheim Pharmaceuticals., Authorship: All authors had access to the data and played a role in writing this manuscript.

Background. The administration of intravenous (IV) calcium to treat hyperkalemia resulting from digoxin poisoning is considered potentially dangerous, based on a body of older literature which, in sum, reported increased cardiac glycoside toxicity with calcium administration (increased arrhythmias, higher rate of death). Objective. This pilot study sought to determine if the administration of calcium chloride when compared to normal saline would affect time to death when given to hyperkalemic, digoxin toxic swine. Methods. Digoxin IV at 0.25 mg/kg was determined to be appropriately toxic for this study. When arrhythmias consistent with hyperkalemia developed, animals were given either IV calcium chloride (CaCl) bolus (10 mg/kg, Group 1, n=6) or normal saline volume equivalent (Group 2, n=6). Three intervals were observed: Interval 1: time interval from digoxin administration (T0) to when ECG changes consistent with hyperkalemia developed (at which point calcium chloride or normal saline was administered); Interval 2: time interval from the development of ECG changes consistent with hyperkalemia to asystole; Interval 3: time interval from digoxin administration to asystole. Both groups were monitored for changes in heart rhythms, serum potassium levels, and time to asystole. Results. The intravenous digoxin dose of 0.25 mg/kg induced hyperkalemia, arrhythmias, and death approximately 1 h after administration in all animals studied. Group 1: Interval 1 averaged 18.75 (S.D. [+ or -] 7.96) rain, Interval 2 averaged 16.75 (S.D. [+ or -] 17.17) min, and Interval 3 averaged 35.5 (S.D. [+ or -] 14.49) min range; Group 2: average Interval 1 24.8 (S.D. [+ or -] 4.71) min, Interval 2 averaged 19.5 (S.D. [+ or -] 15.92), Interval 3 averaged 44.3 (S.D. [+ or -] 13.80) minutes. There was no statistically significant difference between the groups at any time interval, Interval 1 (p=0.43), Interval 2 (p=0.65), Interval 3 (p =0.40). There was no difference in serum potassium throughout the study period. Conclusion. The administration of intravenous CaCl in the setting of hyperkalemia from acute digoxin toxicity did not affect mortality or time to death at the dose administered. Key Words: Digoxin; Toxicity; Potassium; Death., INTRODUCTION Cardiac glycosides interfere with the action of the sodium-potassium ATPase on cardiac myocytes, producing a rise in intracellular calcium due to changes in ion gradients that drive the action [...]

Cardiac glycoside toxicity is frequently associated with hyperkalemia and dysrhythmias in patients with renal insufficiency. Two common therapeutic options for these complications (calcium and transvenous cardiac pacing) are considered contraindicated in the setting of cardiac glycoside toxicity. We present the case of a patient presenting with a pronounced bradydysrhythmia and hyperkalemia who was treated with intravenous calcium and transvenous cardiac pacing and later found to have digitalis toxicity and acute renal failure. There were no adverse events associated with the therapies. The patient received digoxin-specific Fab fragments and hemodialysis as definitive therapeutic modalities. The case and the relevant literature evaluating the interaction of calcium salts and cardiac pacing in the setting of cardiac glycoside toxicity are discussed. Key Words: Digoxin; Toxicity; Hyperkalemia., INTRODUCTION The American Association of Poison Control Centers (AAPCC) received 2963 reports of cardiac glycoside exposure in 1997, with 416 (14%) demonstrating moderate or major morbidity and 12 (0.4%) deaths [...]

Disturbances in potassium homoeostasis presenting as low or high serum potassium are common, especially among hospitalised patients. Given the fact that untreated hypokalaemia or hyperkalaemia is associated with high morbidity [...]

Hyperkalemia is a condition characterized by an excess of serum potassium in the body. It often accompanies renal failure and may also result from severe tissue damage from burns. Patients with aldosterone deficiency, diabetes mellitus and low sodium levels are susceptible to the disease. A potassium level greater than 5.0 indicates hyperkalemia., Excess serum potassium can be lethal. You'll need to recognize its signs and symptoms and act fast. Potassium is necessary for cell metabolism and growth. It's vital to the transmission [...]

A case is described, in which, a California-based biopharmaceutical firm, Ilypsia brought its second polymer drug, ILY105 to Phase II clinical trials in just four years in collaboration with a German custom manufacturer Saltigo. The two companies are looking forward to the product's final stage of clinical testing that would treat hyperkalemia, an elevated potassium condition faced by some kidney disease patients.

To the best of the authors' knowledge, this is the first description of the use of induced hyperkalemic arrest in the perfused heart to achieve cardioplegia for Minimally Invasive Mitral [...]